National Institutes of Health, HHS.
Notice.
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301–496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
(a) To study the biology of stem cell development,
(b) as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases, and
(c) to test different characterization and differentiation assays.
• These cells can serve as control cells and, thus, significantly reduce the cost of initiating many research projects.
• These cells can be a good source of control cells.
• Prototype
• Pilot
• Early-stage
• In vitro data available
Apolipoproteins facilitate the transport of lipids and cholesterol in the body. Mimetics of apolipoproteins have been used to treat cholesterol-related disorders. However, these mimetics are susceptible to degradation in biological fluids and as a result, their ability to bind cholesterol becomes diminished over time.
Scientists at NHLBI have devised methods to stabilize and improve the performance of apolipoprotein mimetic peptides, using a modified hydrocarbon chain (“stapled apolipoproteins”). These stapled apolipoproteins are superior to singular apolipoproteins in that they are more resistant to enzymatic degradation and efflux a greater amount of cellular cholesterol.
Stapled apolipoproteins can be used in the treatment of cardiovascular diseases, particularly for treatment of atherosclerosis.
• Treatment of inflammation and cardiovascular diseases, including hyperlipidemia, atherosclerosis, restenosis, and acute coronary syndrome.
• Inclusion in oral, intravenous or transdermal peptide formulations.
• Stapled apolipoproteins are more resistant to proteolysis and display enhanced bioavailability.
• Stapled apolipoproteins are amenable to oral delivery and have increased permeability to the blood brain barrier.
• Pre-clinical
• In vitro data available
• In vivo data available (animal)
The subject technologies are expression vectors for the production of B19V VP1 and VP2 capsid proteins. Co-expression of the two proteins produce empty virus-like particles (VLPs) that can be used to develop a vaccine against parvovirus B19 and a packaging system for infectious B19V virus. Different expression vectors have been developed and optimized for expression in insects cells and more recently in mammalian cell lines such as 293, Cos7, Hela cells and 293T cells.
• Early-stage
• Pre-clinical
• Clinical
• In vitro data available
• In vivo data available (animal)
• In vivo data available (human)
1. Bernstein DI, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 6;29(43):7357–63. [PMID 21807052]
2. Zhi N, et al. Codon optimization of human parvovirus B19 capsid genes greatly increases their expression in nonpermissive cells. J Virol. 2010 Dec;84(24):13059–62. [PMID 20943969]
• HHS Reference No. E–286–1988/2—U.S. Patent No. 5,916,563 issued 29 Jun 1999
• HHS Reference No. E–286–1988/1—U.S. Patent No. 6,001,371 issued 14 Dec 1999; U.S. Patent No. 6,132,732 issued 17 Oct 2000
• HHS Reference No. E–266–2000/0—U.S. Patent No. 6,558,676 issued 06 May 2003
• HHS Reference No. E–011–2010/0—International PCT Appl. No. PCT/US2011/024199 with national stage filings in the U.S. and Europe